Niti-S Esophageal Stent; Esophageal TTS Stent
Device Facts
| Record ID | K243619 |
|---|---|
| Device Name | Niti-S Esophageal Stent; Esophageal TTS Stent |
| Applicant | Taewoong Medical Co., Ltd. |
| Product Code | ESW · General, Plastic Surgery |
| Decision Date | Oct 30, 2025 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 878.3610 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Niti-S Esophageal Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors and occlusion of concurrent esophageal fistulas. The Esophageal TTS Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors and occlusion of concurrent esophageal fistulas.
Device Story
Device consists of implantable Nitinol wire stent and disposable flexible introducer system. Stent restores esophageal structure/function by exerting outward radial force on luminal surface. Suture attached to one end allows for repositioning during placement. Used in clinical setting by physicians for management of malignant esophageal strictures and fistulas. Introducer system facilitates delivery and deployment. Stent remains in situ to maintain patency. Benefits include relief of obstruction and closure of fistulas. Subject device is identical to predicates except for change in suture material from Nylon to Polyester.
Clinical Evidence
Bench testing only. Biocompatibility testing performed per ISO 10993-1, including cytotoxicity, sensitization, intracutaneous reactivity, acute/subchronic systemic toxicity, pyrogenicity, genotoxicity, and subcutaneous implantation. Performance testing included shelf-life and tensile testing.
Technological Characteristics
Implantable Nitinol wire stent in diamond shape; lengths 60-150mm; midsection diameters 16-22mm; dumbbell diameters 24-28mm. Coverage: Silicone full covered or bare. Radiopaque markers: 8 platinum-iridium, 2 316L stainless steel. Suture: Polyester. Delivery system: Co-axial tube type (OTW or TTS). Sterilization: Ethylene Oxide (EO). No electrical components or software.
Indications for Use
Indicated for patients with esophageal strictures caused by intrinsic and/or extrinsic malignant tumors and occlusion of concurrent esophageal fistulas.
Regulatory Classification
Identification
An esophageal prosthesis is a rigid, flexible, or expandable tubular device made of a plastic, metal, or polymeric material that is intended to be implanted to restore the structure and/or function of the esophagus. The metal esophageal prosthesis may be uncovered or covered with a polymeric material. This device may also include a device delivery system.
Special Controls
The special control for this device is FDA's “Guidance for the Content of Premarket Notification Submissions for Esophageal and Tracheal Prostheses.”
Predicate Devices
Submission Summary (Full Text)
{0}
FDA U.S. FOOD & DRUG ADMINISTRATION
October 30, 2025
Taewoong Medical Co., Ltd.
% Matthew Krueger
Principal Consultant
Biologics Consulting Group
100 Daingerfield Rd, Suite 400
Alexandria, Virginia 22314
Re: K243619
Trade/Device Name: Niti-S Esophageal Stent; Esophageal TTS Stent
Regulation Number: 21 CFR 878.3610
Regulation Name: Esophageal Prosthesis
Regulatory Class: Class II
Product Code: ESW
Dated: September 29, 2025
Received: September 29, 2025
Dear Matthew Krueger:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
{1}
K243619 - Matthew Krueger
Page 2
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
{2}
K243619 - Matthew Krueger
Page 3
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
SIVAKAMI VENKATACHALAM -S
for
Shanil P. Haugen, Ph.D.
Assistant Director
DHT3A: Division of Renal, Gastrointestinal,
Obesity and Transplant Devices
OHT3: Office of Gastrorenal, ObGyn,
General Hospital and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
{3}
Niti-S Esophageal Stent
Page 9 of 46
| Indications for Use | | |
| --- | --- | --- |
| Please type in the marketing application/submission number, if it is known. This
textbox will be left blank for original applications/submissions. | K243619 | ? |
| Please provide the device trade name(s). | | ? |
| Niti-S Esophageal Stent;
Esophageal TTS Stent | | |
| Please provide your Indications for Use below. | | ? |
| The Niti-S Esophageal Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic
malignant tumors and occlusion of concurrent esophageal fistulas.
The Esophageal TTS Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic
malignant tumors and occlusion of concurrent esophageal fistulas. | | |
| Please select the types of uses (select one or both, as
applicable). | ☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? |
{4}
K243619
Page 1 of 7
Traditional 510(k) Summary
Taewoong Medical
Niti-S Esophageal Stent
Esophageal TTS Stent
1. SUBMITTER INFORMATION
Applicant: Taewoong Medical
Contact: Yongjin Jeff Kim
Phone: +82 70 4649 1543
Email: jinjeff@stent.net
Address: 14, Gojeong-ro, Wolgot-myeon, Gimpo-si, Gyeonggi-do, 10022, Republic of Korea
2. CORRESPONDENT INFORMATION
Contact: Matthew Krueger
Title: Principal Consultant
Firm: Biologics Consulting Group
3. DATE PREPARED: SEPTEMBER 25, 2024
4. DEVICE INFORMATION
Device Name: Esophageal TTS Stent
Niti-S Esophageal Stent
Common Name: Prosthesis, Esophageal
Regulation Number: 21 C.F.R. 878.3610
Regulation Name: Esophageal prosthesis
Product Code: ESW
Regulatory Class: Class II
5. PREDICATE DEVICE INFORMATION
Device Name: Esophageal TTS Stent, Niti-S Esophageal Stent
510(k) Number: K240522, K080782
Manufacturer: Taewoong Medical
The predicate devices have not been subject to a design related recall.
{5}
K243619
Page 2 of 7
Traditional 510(k) Summary
Taewoong Medical
Niti-S Esophageal Stent
Esophageal TTS Stent
# 6. DEVICE DESCRIPTION
The Esophageal TTS Stents and Niti-S Esophageal Stents that are the subject of this 510(k) are identical to the devices cleared in K240522 and K080782, respectively, with the exception of the change in suture material for both stents. The indications for use for the Niti-S Esophageal Stent have also been updated to align with those of the Esophageal TTS Stents.
The Esophageal TTS Stents and Niti-S Esophageal Stents consist of an implantable metallic stent and a disposable, flexible introducer system for placement of the stent. The stent is a flexible and expandable tubular device made of Nitinol wire that is intended to be implanted to restore the structure and/or function of the esophagus. The introducer is a disposable system for delivery and deployment of the stent at the target position. Upon deployment, the stent imparts an outward radial force on the luminal surface of the esophagus to establish patency. A length of suture is attached to one end of the stent and can be used for stent repositioning during initial placement, in accordance with the instructions for use.
# 7. INDICATIONS FOR USE
The Esophageal TTS Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors and occlusion of concurrent esophageal fistulas.
The Niti-S Esophageal Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors and occlusion of concurrent esophageal fistulas.
# 8. COMPARISON OF INTENDED USE AND TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
The table below compares the intended use and the technological characteristics of the subject device and predicate device.
Table 1: Comparator Table for Subject and Predicate Devices
| | Subject Device | Predicate Device K080782, K240522 | Comments |
| --- | --- | --- | --- |
| Device Name | Niti-S Esophageal Stent, Esophageal TTS Stent | Niti-S Esophageal Stent (K080782), Esophageal TTS Stent (K240522) | Identical |
| Common Name | Esophageal Stent | Esophageal Stent | Identical |
| Manufacturer | Taewoong Medical Co., Ltd | Taewoong Medical Co., Ltd | Identical |
| Product Code | ESW | ESW | Identical |
| Regulation | 21 CFR 878.3610 Esophageal prosthesis | 21 CFR 878.3610 Esophageal prosthesis | Identical |
{6}
K243619
Page 3 of 7
Traditional 510(k) Summary
Taewoong Medical
Niti-S Esophageal Stent
Esophageal TTS Stent
| | Subject Device | Predicate Device K080782, K240522 | Comments |
| --- | --- | --- | --- |
| Indications for use | Niti-S Esophageal Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors and occlusion of concurrent esophageal fistulas.
Esophageal TTS Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors and occlusion of concurrent esophageal fistulas. | (K080782) Niti-S Esophageal Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors.
(K240522) Esophageal TTS Stent is intended for use in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors and occlusion of concurrent esophageal fistulas. | **Substantially Equivalent:**
• Original use of K080782: esophageal strictures from malignant tumors
• Now includes: “occlusion of concurrent esophageal fistulas”. This indication was previously cleared for the identical stent implant as cleared in K240522.
• Stent Justification:
o Same materials
o Same design
o Same purposes
o Same target site
o Same manufacturing process
• Therefore, the Niti-S Esophageal Stent with the modified Indications for Use is Substantially Equivalent to the previously cleared Esophageal TTS Stent (K240522). |
Page 3 of 7
{7}
K243619
Page 4 of 7
Traditional 510(k) Summary
Taewoong Medical
Niti-S Esophageal Stent
Esophageal TTS Stent
| | Subject Device | Predicate Device K080782, K240522 | Comments |
| --- | --- | --- | --- |
| Design (Stents) | | | **Substantially Equivalent:**
- Dimensionally the same
- General design is the same
- Only the suture material has changed from Nylon to Polyester
- Performance testing, biocompatibility testing, and shelf life testing demonstrate that the change in suture material does not affect safety or effectiveness of the device. Thus, the stent with the modified suture material is substantially equivalent to the predicate device. |
| | - Nitinol wire in diamond shape
- Lengths: 60 mm, 80 mm, 100 mm, 120 mm, 140 mm, 150 mm
- Midsection Diameters: 16 mm, 18 mm, 20 mm, 22 mm
- Dumbbell Diameters: 24 mm, 26 mm, 28 mm
- Coverage: Silicone Full Covered, Silicone Both Bare
- Radiopaque Markers: 8 platinum-iridium markers and 2 316L stainless steel markers
- Suture material: Polyester | - Nitinol wire in diamond shape
- Lengths: 60 mm, 80 mm, 100 mm, 120 mm, 140 mm, 150 mm
- Midsection Diameters: 16 mm, 18 mm, 20 mm, 22 mm
- Dumbbell Diameters: 24 mm, 26 mm, 28 mm
- Coverage: Silicone Full Covered, Silicone Both Bare
- Radiopaque Markers: 8 platinum-iridium markers and 2 316L stainless steel markers
- Suture material: Nylon | |
Page 4 of 7
{8}
K243619
Page 5 of 7
Traditional 510(k) Summary
Taewoong Medical
Niti-S Esophageal Stent
Esophageal TTS Stent
| | Subject Device | Predicate Device K080782, K240522 | Comments |
| --- | --- | --- | --- |
| Design (Introducer) | **Niti-S Esophageal Stent**
OTW (Over-The-Wire) type
Stent Delivery System
Co-axial tube type
Usable Length: 70cm
Diameter: 16 Fr (5.3mm), 20 Fr (6.7mm)
**Esophageal TTS Stent**
TTS (Through-The-Scope) type
Stent Delivery System
Co-axial tube type
Usable Length: 180 and 220cm
Diameter: 10.5 Fr (3.5mm) | **Niti-S Esophageal Stent**
(K080782) OTW (Over-The-Wire) type Stent Delivery System
Co-axial tube type
Usable Length: 70cm
Diameter: 16 Fr (5.3mm), 20 Fr (6.7mm)
**Esophageal TTS Stent**
(K240522) TTS (Through-The-Scope) type Stent Delivery System | Identical |
| Single Use | Yes | Yes | Identical |
| Sterile | EO Sterilization | EO Sterilization | Identical |
| Method of Placement | OTW (Over-The-Wire),
TTS (Through-The-Scope) | OTW (Over-The-Wire),
TTS (Through-The-Scope) | Identical |
| Method of Deployment | Release by pulling outer sheath | Release by pulling outer sheath | Identical |
| Packaging | PET tray with Tyvek lid placed in
a Tyvek pouch and then placed
inside of a Manila paper box | PET tray with Tyvek lid placed in
a Tyvek pouch and then placed
inside of a Manila paper box | Identical |
## 9. SUMMARY OF NON-CLINICAL PERFORMANCE TESTING
### Biocompatibility Testing
Biocompatibility testing per ISO 10993-1 and FDA Guidance was performed to demonstrate the biological safety of the subject stents with the new polyester suture material.
Page 5 of 7
{9}
K243619
Page 6 of 7
Traditional 510(k) Summary
Taewoong Medical
Niti-S Esophageal Stent
Esophageal TTS Stent
Stent materials are considered implants in contact with tissue for > 30 days.
Table 2 outlines the testing conducted.
Table 2: Biocompatibility Testing Conducted
| Test | Standard |
| --- | --- |
| Cytotoxicity
MEM Extract | ISO 10993-5:2009 |
| Sensitization
Guinea pig maximization test | ISO 10993-10:2021 |
| Intracutaneous Reactivity
New Zealand rabbit | ISO 10993-23:2021 |
| Acute Systemic Toxicity
ICR mice | ISO 10993-11:2017 |
| Pyrogen Test
New Zealand rabbit | ISO 10993-11:2017
USP <151> |
| 90-Day Subchronic Systemic Toxicity
Rats | ISO 10993-11: 2017 |
| In Vitro Mammalian Chromosomal Aberration (Genotoxicity)
Chinese hamster lung cell line (CHL) | ISO 10993-3: 2015
ISO/TR 10993-33: 2015 |
| Bacterial Reverse Mutation
(Genotoxicity) | ISO 10993-3: 2015
ISO/TR 10993-33: 2015 |
| 4-Week Subcutaneous Implantation Testing
Rats | ISO 10993-6: 2018 |
| 13-Week Subcutaneous Implantation Testing
Rats | ISO 10993-6: 2018 |
| Chemical Characterization
Exhaustive extraction | ISO 10993-18:2020 |
## Electrical Safety
Not applicable. The subject device contains no electric components, generates no electrical emissions, and uses no electrical energy of any type.
## Electromagnetic Compatibility (EMC)
Not applicable. The subject device contains no electric components, generates no electrical emissions, and uses no electrical energy of any type.
## Software
Not applicable. The subject device contains no software.
Page 6 of 7
{10}
K243619
Page 7 of 7
Traditional 510(k) Summary
Taewoong Medical
Niti-S Esophageal Stent
Esophageal TTS Stent
## Performance Testing
Other performance testing was conducted to show that the device meets its design requirements and performs as intended. The performance tests include:
- Shelf-life testing
- Tensile testing
## 10. CONCLUSION
Based on the non-clinical performance and biocompatibility testing, the Esophageal TTS Stents and Niti-S Esophageal Stents are as safe and effective as the predicate devices and support a determination of substantial equivalence.
Page 7 of 7
